Breast MRI and18F FDG PET/CT in the management of breast cancer

Iagaru, Andrei; Masamed, Rinat; Keesara, Sravanthi R.; Conti, Peter S.

doi:10.1007/bf03033997

Cited by 32 publications

(18 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well-established that 18 F-FDG PET imaging is a powerful tool for assisting in the diagnosis, staging, and monitoring of therapy response for a variety of neoplastic processes, including breast cancer (23,24). One of the main limitations of the current use of PET imaging is that our standard practice of preoperative image acquisition at the time of the original evaluation of the patient cannot be translated into real-time information for availability in the …”

Section: Discussionmentioning

confidence: 99%

PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach

Orsaria

Chiaravalloti

Fiorentini

et al. 2017

View full text Add to dashboard Cite

Nuclear medicine has an essential and increasing role in the management of patients with breast cancer. Sentinel node detection has achieved reliability and, at present, it has an important place in clinical management. Even in the era of gene-expression profiling, nodal status remains one of the primary prognostic discriminants in patients with breast cancer, and is of great value as an independent predictor of distant disease development. Although several institutional case series have differed in patient selection, follow-up, type of surgery, and adjuvant therapies, they have consistently shown that the percentage of positive lymph nodes is a significant indicator of survival in women with axillary metastases on final pathology (1-5). The American Society of Clinical Oncology convened an Update Committee of experts to provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer (6). The need to perform axillary lymph node dissection (ALND) when SNB is positive and administration of contemporary adjuvant treatment including radiotherapy, chemotherapy, and hormonal therapy has been questioned in recent years. On the other hand, ongoing trials are testing whether node-positive patients can be spared chemotherapy, as qualifying indications increasingly rely on breast cancer biology for decision-making regarding adjuvant systemic treatment (7). In summary, sentinel node surgery represents the next major step in reducing the extent of surgical procedures, but despite the revolution of quality-conserving care, recent data collection and analyses of anatomical techniques suggest that exact lymphatic drainage of the breast is debatable (8). Different lymphatic patterns may help explain some important unresolved clinical problems, including different detection rates between studies and high false-negative rates of about 10% in multicenter randomized controlled trials (9). Further anatomical investigation and knowledge of the exact sentinel lymphatic channels will provide more information about patterns of breast cancer in order to improve surgical strategy, locoregional recurrence, and survival.

show abstract

Section: Discussionmentioning

confidence: 99%

PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach

Orsaria

Chiaravalloti

Fiorentini

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Pathologic sampling or follow-up imaging results were used as confi rmation in all cases. 40 Details of these cases, including the presence or absence of other features that might have suggested metastasis, are not available. A prospective study comparing FDG-PET for inbreast and systemic staging with chest x-ray, liver ultrasound, mammography, and bone scan noted a greater sensitivity of FDG-PET in inbreast staging for detecting malignant lesions, in detecting multifocality, and in correctly identifying metastatic disease in seven patients, with no false-positives or false-negatives found in 117 cases.…”

Section: Evaluating For Distant Metastasismentioning

confidence: 97%

Cost-Effective Staging of Breast Cancer

Borges¹,

Hardesty²

2011

Early Diagnosis and Treatment of Cancer Series: Breast Cancer

View full text Add to dashboard Cite

“…For example, when combining MRI and PET, we can exploit the best of each modality's characteristics to better understand both normal tissue behavior and tumor response to treatment. A few studies have investigated the use of combined MRI and PET to monitor and assess residual disease in locally advanced breast cancer during PST (41,51,(57)(58)(59)(60)(61). In these studies, there were significant decreases in the MRI and SUV metrics in responders compared with nonresponders.…”

Section: Multiparametric and Multimodality Imaging Of Treatment Respomentioning

confidence: 99%

Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment

et al. 2015

View full text Add to dashboard Cite

Breast cancer is the second leading cause of cancer death among US women, and the chance of a woman developing breast cancer sometime during her lifetime is one in eight. Early detection and diagnosis to allow appropriate locoregional and systemic treatment are key to improve the odds of surviving its diagnosis. Emerging data also suggest that different breast cancer subtypes (phenotypes) may respond differently to available adjuvant therapies. There is a growing understanding that not all patients benefit equally from systemic therapies, and therapeutic approaches are being increasingly personalized based on predictive biomarkers of clinical benefit. Optimal use of established and novel radiological imaging methods, such as magnetic resonance imaging and positron emission tomography, which have different biophysical mechanisms can simultaneously identify key functional parameters. These methods provide unique multiparametric radiological signatures of breast cancer, that will improve the accuracy of early diagnosis, help select appropriate therapies for early stage disease, and allow early assessment of therapeutic benefit.

show abstract

Breast MRI and18F FDG PET/CT in the management of breast cancer

Cited by 32 publications

References 20 publications

PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach

PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach

Cost-Effective Staging of Breast Cancer

Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment

Contact Info

Product

Resources

About